Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation

a case control study

Yakir Segev, Barry Rosen, Jan Lubinski, Jacek Gronwald, Henry T. Lynch, Pal Moller, Charmaine Kim-Sing, Parviz Ghadirian, Beth Karlan, Charis Eng, Dawna Gilchrist, Susan L. Neuhausen, Andrea Eisen, Eitan Friedman, David Euhus, Sun Ping, Steven A. Narod

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 % CI 0.03–1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 % CI 0.99–98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 % CI 1.51–8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.

Original languageEnglish
Pages (from-to)383-391
Number of pages9
JournalFamilial Cancer
Volume14
Issue number3
DOIs
StatePublished - Apr 3 2015

Fingerprint

Endometrial Neoplasms
Case-Control Studies
Hormone Replacement Therapy
Mutation
Tamoxifen
Oral Contraceptives
Odds Ratio
Menarche
Menopause
Progesterone
Multivariate Analysis
Breast Neoplasms
Ovariectomy
Hysterectomy
Ovarian Neoplasms
Uterus
Registries
Estrogens
Smoking
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Genetics
  • Oncology
  • Genetics(clinical)

Cite this

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation : a case control study. / Segev, Yakir; Rosen, Barry; Lubinski, Jan; Gronwald, Jacek; Lynch, Henry T.; Moller, Pal; Kim-Sing, Charmaine; Ghadirian, Parviz; Karlan, Beth; Eng, Charis; Gilchrist, Dawna; Neuhausen, Susan L.; Eisen, Andrea; Friedman, Eitan; Euhus, David; Ping, Sun; Narod, Steven A.

In: Familial Cancer, Vol. 14, No. 3, 03.04.2015, p. 383-391.

Research output: Contribution to journalArticle

Segev, Y, Rosen, B, Lubinski, J, Gronwald, J, Lynch, HT, Moller, P, Kim-Sing, C, Ghadirian, P, Karlan, B, Eng, C, Gilchrist, D, Neuhausen, SL, Eisen, A, Friedman, E, Euhus, D, Ping, S & Narod, SA 2015, 'Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study', Familial Cancer, vol. 14, no. 3, pp. 383-391. https://doi.org/10.1007/s10689-015-9798-8
Segev, Yakir ; Rosen, Barry ; Lubinski, Jan ; Gronwald, Jacek ; Lynch, Henry T. ; Moller, Pal ; Kim-Sing, Charmaine ; Ghadirian, Parviz ; Karlan, Beth ; Eng, Charis ; Gilchrist, Dawna ; Neuhausen, Susan L. ; Eisen, Andrea ; Friedman, Eitan ; Euhus, David ; Ping, Sun ; Narod, Steven A. / Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation : a case control study. In: Familial Cancer. 2015 ; Vol. 14, No. 3. pp. 383-391.
@article{4bdb1be51a35418e952708a36e73eea5,
title = "Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study",
abstract = "BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 {\%} CI 0.03–1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 {\%} CI 0.99–98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 {\%} CI 1.51–8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.",
author = "Yakir Segev and Barry Rosen and Jan Lubinski and Jacek Gronwald and Lynch, {Henry T.} and Pal Moller and Charmaine Kim-Sing and Parviz Ghadirian and Beth Karlan and Charis Eng and Dawna Gilchrist and Neuhausen, {Susan L.} and Andrea Eisen and Eitan Friedman and David Euhus and Sun Ping and Narod, {Steven A.}",
year = "2015",
month = "4",
day = "3",
doi = "10.1007/s10689-015-9798-8",
language = "English",
volume = "14",
pages = "383--391",
journal = "Familial Cancer",
issn = "1389-9600",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation

T2 - a case control study

AU - Segev, Yakir

AU - Rosen, Barry

AU - Lubinski, Jan

AU - Gronwald, Jacek

AU - Lynch, Henry T.

AU - Moller, Pal

AU - Kim-Sing, Charmaine

AU - Ghadirian, Parviz

AU - Karlan, Beth

AU - Eng, Charis

AU - Gilchrist, Dawna

AU - Neuhausen, Susan L.

AU - Eisen, Andrea

AU - Friedman, Eitan

AU - Euhus, David

AU - Ping, Sun

AU - Narod, Steven A.

PY - 2015/4/3

Y1 - 2015/4/3

N2 - BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 % CI 0.03–1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 % CI 0.99–98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 % CI 1.51–8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.

AB - BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 % CI 0.03–1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 % CI 0.99–98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 % CI 1.51–8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.

UR - http://www.scopus.com/inward/record.url?scp=84941023298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941023298&partnerID=8YFLogxK

U2 - 10.1007/s10689-015-9798-8

DO - 10.1007/s10689-015-9798-8

M3 - Article

VL - 14

SP - 383

EP - 391

JO - Familial Cancer

JF - Familial Cancer

SN - 1389-9600

IS - 3

ER -